Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.
Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.
Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):719-726. doi: 10.1016/j.ijrobp.2022.03.018. Epub 2022 Mar 30.
In 2017, the American Society for Radiation Oncology (ASTRO) board of directors prioritized radiopharmaceutical therapy (RPT) as a leading area for new therapeutic development, and the ASTRO RPT workgroup was created. Herein, the workgroup has developed a framework for RPT curriculum development upon which education leaders can build to integrate this modality into radiation oncology resident education. Through this effort, the workgroup aims to provide a guide to ensure robust training in an emerging therapeutic area within the context of existing radiation oncology training in radiation biology, medical physics, and clinical radiation oncology. The framework first determines the core RPT knowledge required to select patients, prescribe, safely administer, and manage related adverse events. Then, it defines the most important topics for preparing residents for clinical RPT planning and delivery. This framework is designed as a tool to supplement the current training that exists for radiation oncology residents. The final document was approved by the ASTRO board of directors in the fall of 2021.
2017 年，美国放射肿瘤学会（ASTRO）理事会将放射性药物治疗（RPT）列为新治疗方法开发的重点领域，并成立了 ASTRO RPT 工作组。在此基础上，工作组制定了一个 RPT 课程开发框架，教育领导者可以在此基础上构建，将该模式纳入放射肿瘤学住院医师教育。通过这一努力，工作组旨在提供一个指南，以确保在现有的放射肿瘤学培训中，在放射生物学、医学物理学和临床放射肿瘤学的背景下，对新兴治疗领域进行强有力的培训。该框架首先确定了选择患者、处方、安全给药和管理相关不良反应所需的核心 RPT 知识。然后，它定义了为准备住院医师进行临床 RPT 规划和提供服务而最重要的主题。该框架旨在作为补充现有放射肿瘤学住院医师培训的工具。该文件最终于 2021 年秋季获得 ASTRO 理事会的批准。
